Related to IOM Guidelines for Use of Omics Tests in Clinical Trials Add Rigor to Quality Assurance

• Clarient, Acorn Ally to Standardize Cancer Testing
  
• Ezose, Merck & Co. Ink Diabetes Biomarker Deal
  
• Ventana, Advanced Cell Diagnostics Ally for Automated RNA In Situ Hybridization Assays
  
• Lineagen, Fast Forward Team Up to Develop MS Tests
  
• TrovaGene Gains Rights to Mutations Associated with Chronic Lymphocytic Leukemia
  
• Qiagen and Max Planck to Develop Test to Assess Active TB Risk
  
• Foundation and Sanofi Sign Deal for Cancer Biomarkers and Companion Diagnostics
  
• Qiagen Signs Two Biomarker Deals and Confirms Japanese Okay for EGFR Companion Dx
  
• Evotec, Harvard, and Brigham & Women’s Partner on Kidney Diseases
  
• MDxHealth Awarded CLIA Certification for Irvine Laboratory
  
• Amarantus Pays Power3 $0.5M for Biomarker IP to Diagnose Parkinson Disease
  
• EMD Millipore, Proteomics International to Validate Diabetic Nephropathy Biomarkers
  
• OGT Licenses 12 Colorectal Cancer DNA Methylation Biomarkers from Oslo University
  
• GSK Taps Epistem for Amplification Platform to Identify Fibrosis Biomarkers
  
• Proteome Sciences to Carry Out Biomarker Analyses for €11M EU-Funded Stroke Hypothermia Trial
  
• Alzheimer’s Association Puts $4.2M into Initiative to Speed Drug, Biomarker Trials
  
• Enterome Raises €5M to Develop Gut Bacteria-Based Disease and Drug-Response Biomarkers
  
• Affymetrix to Distribute Almac’s Expression-Profiling Array for FFPE Samples
  
• Asuragen to Receive $6.8M from the Cancer Prevention and Research Institute of Texas
  
• Ezose, Hirosaki University Sign Glycomics Partnership to Identify Urologic Cancer Biomarkers